The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
ERCC1 Isoform Expression and DNA Repair in Non–Small-Cell Lung Cancer
Open accessAbstract
BACKGROUND: The excision repair cross-complementation group 1 (ERCC1) protein is a potential prognostic biomarker of the efficacy of cisplatin-based chemotherapy in non-small-cell lung cancer (NSCLC). Although several ongoing trials are evaluating the level of expression of ERCC1, no consensus has been reached regarding a method for evaluation. METHODS: We used the 8F1 antibody to measure the level of expression of ERCC1 protein by means of immunohistochemical analysis in a validation set of samples obtained from 494 patients in two independent phase 3 trials (the National Cancer Institute of Canada Clinical Trials Group JBR.10 and the Cancer and Leukemia Group B 9633 trial from the Lung Adjuvant Cisplatin Evaluation Biology project). We compared the results of repeated staining of the entire original set of samples obtained from 589 patients in the International Adjuvant Lung Cancer Trial Biology study, which had led to the initial correlation between the absence of ERCC1 expression and platinum response, with our previous results in the same tumors. We mapped the epitope recognized by 16 commercially available ERCC1 antibodies and investigated the capacity of the different ERCC1 isoforms to repair platinum-induced DNA damage. RESULTS: We were unable to validate the predictive effect of immunostaining for ERCC1 protein. The discordance in the results of staining for ERCC1 suggested a change in the performance of the 8F1 antibody since 2006. We found that none of the 16 antibodies could distinguish among the four ERCC1 protein isoforms, whereas only one isoform produced a protein that had full capacities for nucleotide excision repair and cisplatin resistance. CONCLUSIONS: Immunohistochemical analysis with the use of currently available ERCC1 antibodies did not specifically detect the unique functional ERCC1 isoform. As a result, its usefulness in guiding therapeutic decision making is limited. (Funded by Eli Lilly and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Pignon, J.-P., Tribodet, H., Scagliotti, G. V., Douillard, J.-Y., Shepherd, F. A., Stephens, R. J., Dunant, A., Torri, V., Rosell, R., Seymour, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9030 · Cited by 2,642
Self-citation(2004) · New England Journal of Medicine · doi:10.1056/nejmoa031644 · Cited by 2,335
Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer
Winton, T., Livingston, R., Johnson, D., Rigas, J., Johnston, M., Butts, C., Cormier, Y., Goss, G., Inculet, R., Vallieres, E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043623 · Cited by 1,810
Self-citationDNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy
Olaussen, K. A., Dunant, A., Fouret, P., Brambilla, E., André, F., Haddad, V., Taranchon, E., Filipits, M., Pirker, R., Popper, H. H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060570 · Cited by 1,727
Self-citationStrauss, G. M., Herndon, J. E., Maddaus, M. A., Johnstone, D. W., Johnson, E. A., Harpole, D. H., Gillenwater, H. H., Watson, D. M., Sugarbaker, D. J., Schilsky, R. L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.4855 · Cited by 974
Lord, R. V., Brabender, J., Gandara, D. R., Alberola, V., Camps, C., Dómine, M., Cardenal, F., Sánchez, J. M., Gumerlock, P. H., Tarón, M., et al. (2002) · PubMed · Cited by 668
DNA Synthesis and Repair Genes RRM1 and ERCC1 in Lung Cancer
Zheng, Z., Chen, T., Li, X., Haura, E., Sharma, A., & Bepler, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065411 · Cited by 462
Cobo, M., Isla, D., Massuti, B., Montes, A., Sanchez, J. M., Provencio, M., Viñolas, N., Paz-Ares, L., Lopez-Vivanco, G., Muñoz, M. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.7915 · Cited by 443
ERCC1 Expression Is a Predictor of Survival in Resected Patients With Non-small Cell Lung Cancer
Simon, G. R., Sharma, S., Cantor, A., Smith, P., & Bepler, G. (2005) · Chest · doi:10.1378/chest.127.3.978 · Cited by 277
Cited by
Postmus, P. E., Kerr, K. M., Oudkerk, M., Senan, S., Waller, D. A., Vansteenkiste, J., Escriu, C., & Peters, S. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx222 · Cited by 2,302
Lord, C. J., & Ashworth, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.21 · Cited by 1,257
Systems biology of cisplatin resistance: past, present and future
Galluzzi, L., Vitale, I., Michels, J., Brenner, C., Szabadkai, G., Harel-Bellan, A., Castedo, M., & Kroemer, G. (2014) · Cell Death & Disease · doi:10.1038/cddis.2013.428 · Cited by 782
“However, none of these factors has yet been validated as a reliable clinical predictor of CDDP sensitivity.(124) Alongside, the abundance of transcripts coding for several proteins that have no obvious links with CDDPelicited signaling pathway has been correlated with clinical CDDP resistance.”
BackgroundManagement of non-small-cell lung cancer: recent developments
Reck, M., Heigener, D. F., Mok, T., Soria, J.-C., & Rabe, K. F. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61502-0 · Cited by 714
Self-citationSomatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma
Van Allen, E. M., Mouw, K. W., Kim, P., Iyer, G., Wagle, N., Al-Ahmadie, H., Zhu, C., Ostrovnaya, I., Kryukov, G. V., O'Connor, K. W., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0623 · Cited by 620
Vansteenkiste, J. F., Cho, B. C., Vanakesa, T., De Pas, T., Zielinski, M., Kim, M. S., Jassem, J., Yoshimura, M., Dahabreh, J., Nakayama, H., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00099-1 · Cited by 511
Vansteenkiste, J., De Ruysscher, D., Eberhardt, W. E. E., Lim, E., Senan, S., Felip, E., & Peters, S. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt241 · Cited by 490
Liu, Y., Zheng, C., Huang, Y., He, M., Xu, W. W., & Li, B. (2021) · MedComm · doi:10.1002/mco2.55 · Cited by 387
Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer
Fennell, D. A., Summers, Y., Cadranel, J., Benepal, T., Christoph, D. C., Lal, R., Das, M., Maxwell, F., Visseren-Grul, C., & Ferry, D. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.01.003 · Cited by 382
Lung Cancer Staging and Prognosis
Woodard, G. A., Jones, K. D., & Jablons, D. M. (2016) · Cancer Treatment and Research · doi:10.1007/978-3-319-40389-2_3 · Cited by 366
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer
Chabanon, R. M., Muirhead, G., Krastev, D. B., Adam, J., Morel, D., Garrido, M., Lamb, A., Hénon, C., Dorvault, N., Rouanne, M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci123319 · Cited by 332
“To address this hypothesis in a relatively unbiased fashion, we first used RNA sequencing (RNA-Seq) to profile the transcriptome of isogenic ERCC1-defective and wildtype A549 NSCLC cells (31, 32).”
BackgroundMethodInfluentialSelf-citationRefining the treatment of NSCLC according to histological and molecular subtypes
Thomas, A., Liu, S. V., Subramaniam, D. S., & Giaccone, G. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.90 · Cited by 321
Platinum Resistance in Ovarian Cancer: Role of DNA Repair
Damia, G., & Broggini, M. (2019) · Cancers · doi:10.3390/cancers11010119 · Cited by 298
Kerr, K. M., Bubendorf, L., Edelman, M. J., Marchetti, A., Mok, T., Novello, S., O'Byrne, K., Stahel, R., Peters, S., Felip, E., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu145 · Cited by 298
Self-citationTsao, M.-S., Marguet, S., Le Teuff, G., Lantuejoul, S., Shepherd, F. A., Seymour, L., Kratzke, R., Graziano, S. L., Popper, H. H., Rosell, R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.8335 · Cited by 267
Self-citationAhn, J. S., Ahn, Y. C., Kim, J.-H., Lee, C. G., Cho, E. K., Lee, K. C., Chen, M., Kim, D.-W., Kim, H.-K., Min, Y. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0130 · Cited by 261
Drug resistance in pancreatic cancer: Impact of altered energy metabolism
Grasso, C., Jansen, G., & Giovannetti, E. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.03.026 · Cited by 253
Bradbury, A. R. M., Trinklein, N. D., Thie, H., Wilkinson, I. C., Tandon, A. K., Anderson, S., Bladen, C. L., Jones, B., Aldred, S. F., Bestagno, M., et al. (2018) · mAbs · doi:10.1080/19420862.2018.1445456 · Cited by 121
Metadata
- Authors
- Friboulet, L., Olaussen, K. A., Pignon, J.-P., Shepherd, F. A., Tsao, M.-S., Graziano, S., Kratzke, R., Douillard, J.-Y., Seymour, L., Pirker, R., Filipits, M., André, F., Solary, E., Ponsonnailles, F., Robin, A., Stoclin, A., Dorvault, N., Commo, F., Adam, J., Vanhecke, E., Saulnier, P., Thomale, J., Le Chevalier, T., Dunant, A., Rousseau, V., Le Teuff, G., Brambilla, E., & Soria, J.-C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-03-21
- Volume
- 368
- Issue
- 12
- Pages
- 1101-1110
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2010624323
- Cited by
- 371
- References
- 29
- FWCI
- 47.74
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.